Extended tamoxifen therapy may increase risk of endometrial cancer

July 5, 2018, Wiley

There is clear evidence that extended adjuvant tamoxifen therapy for 10 years reduces local recurrence and improves breast cancer-free survival in women with oestrogen receptor-positive breast cancer. An analysis of large randomized controlled trials, however, reveals that extended use is linked with a two-fold increased risk of developing endometrial (womb) cancer, when compared with standard 5 years of tamoxifen.

While more research is needed, the BJS (British Journal of Surgery) findings suggest that screening for endometrial cancer may be warranted in patients who receive extended .

"There is a paucity of clear evidence on how we should best manage endometrial cancer risk in extended therapy. This is a research area that requires immediate focus with expansion of extended tamoxifen therapy regimes," said lead author Dr. Christina Fleming, of St. Vincent's Hospital Group, in Dublin, Ireland.

Explore further: Surgery benefits older women with breast cancer

More information: C. A. Fleming et al, Meta-analysis of the cumulative risk of endometrial malignancy and systematic review of endometrial surveillance in extended tamoxifen therapy, British Journal of Surgery (2018). DOI: 10.1002/bjs.10899

Related Stories

Surgery benefits older women with breast cancer

May 23, 2018
In a BJS (British Journal of Surgery) analysis of 18,730 older patients with oestrogen receptor- positive breast cancer in the UK, the risk of dying from breast cancer was greater in patients treated with primary endocrine ...

ASCO: ovarian suppression + tamoxifen ups breast CA survival

June 5, 2018
(HealthDay)—The addition of ovarian suppression to tamoxifen is associated with increased survival versus tamoxifen alone among premenopausal women with breast cancer, according to a study published online June 4 in the ...

Study confirms long term benefits of tamoxifen

June 3, 2013
(Medical Xpress)—Taking tamoxifen for 10 rather than five years halves the risk of women dying from the most common kind of breast cancer, according to new research being presented at this year's ASCO conference.

Tamoxifen, AI therapies linked to reduced risk for contralateral breast cancer in community health

October 6, 2016
In patients with invasive breast cancer treated in a general community health care setting, tamoxifen therapy was associated with reduced risTamoxifen, AI therapies linked to reduced risk for contralateral breast cancer in ...

Cholesterol lowering Rx cuts recurrence in breast cancer

February 15, 2017
(HealthDay)—For women with early-stage, hormone receptor-positive invasive breast cancer, initiation of cholesterol-lowering medication (CLM) during endocrine therapy is associated with improved survival and distant recurrence-free ...

Tamoxifen trial should prompt breast cancer patients to reconsider treatment options

December 6, 2012
A groundbreaking clinical trial involving the breast cancer drug tamoxifen should prompt certain breast cancer patients to reconsider their treatment options, according to Loyola University Medical Center breast cancer specialist ...

Recommended for you

Surgeons have substantial impact on genetic testing in breast cancer patients who need it

July 3, 2018
For many women diagnosed with breast cancer, genetic testing can offer important information that might guide treatment choices. But studies have shown that only about half of women who could benefit receive genetic testing.

First major study comparing robotic to open surgery published in The Lancet

June 21, 2018
The first comprehensive study comparing the outcomes of robotic surgery to those of traditional open surgery in any organ has found that the surgeries are equally effective in treating bladder cancer. The seven-year study, ...

Antibodies may predict transplant rejection risk

June 19, 2018
The presence of certain antibodies in patients may suggest a higher risk of transplant rejection across multiple organ types, including the kidney, liver, heart and lungs, according to a new study published in PLOS Medicine.

First human test of robotic eye surgery a success

June 18, 2018
Researchers from the University of Oxford have completed the first successful trial of robot-assisted retinal surgery.

Surgical blood transfusions tied to clot risk

June 13, 2018
(HealthDay)—Blood transfusions around the time of surgery may raise your risk for dangerous blood clots, researchers say.

Tonsil and adenoid removal associated with respiratory, allergic and infectious disease

June 7, 2018
Tonsil and adenoid removal associated with long-term risks of respiratory, allergic and infectious diseases Removing tonsils and adenoids in childhood increases the long-term risk of respiratory, allergic and infectious diseases, ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.